Search
Ubrogepant
go.drugbank.com/drugs/DB15328ApprovedInvestigational[A189207] Ubrogepant was approved by Health Canada on November 10, 2022. … [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 InhibitorsRemibrutinib
go.drugbank.com/drugs/DB16852ApprovedInvestigationalThe FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. … [A274501, L54101] Remibrutinib has also been investigated in other inflammatory conditions,[A274511] such as autoimmune encephalomyelitis [A274501] and Sjögren's syndrome.[A274521]
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 SubstratesDonislecel
go.drugbank.com/drugs/DB17961Approved[L47196] Overall, 21 patients achieved insulin independence for a year or more, with 11 patients not needing insulin for 1 to 5 years and 10 patients for more than 5 years. … [L47166,L47196] The approval of donislecel was based on the safety and effectiveness evaluated in 2 clinical trials with 30 type 1 diabetic patients.
Pradefovir mesylate
go.drugbank.com/drugs/DB05478InvestigationalPradefovir mesilate (previously known as MB-06886, Hepavir B and remofovir mesylate) is an orally administered small molecule compound that belongs to a novel series of phosphate and phosphonate prodrugs … Pradefovir is activated through oxidation that is mediated by cytochrome P-450 (CYP) 3A4, which is predominantly expressed in the liver.
MGD-024
go.drugbank.com/drugs/DB17265InvestigationalMGD-024 is an anti-CD123/anti-CD3 bispecific DART molecule.
Sodium channel protein type 10 subunit alpha
go.drugbank.com/bio_entities/BE0000177TargetHumansTetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sod...
Polypeptides: Sodium channel protein type 10 subunit alphaATP-sensitive inward rectifier potassium channel 10
go.drugbank.com/bio_entities/BE0009591TargetHumansMay be responsible for potassium buffering action of glial cells in the brain (By similarity). Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it (Pu...
Polypeptides: ATP-sensitive inward rectifier potassium channel 10Synonyms: Potassium channel, inwardly rectifying subfamily J member 10Mitogen-activated protein kinase kinase kinase 10
go.drugbank.com/bio_entities/BE0009462TargetHumansActivates the JUN N-terminal pathway
Polypeptides: Mitogen-activated protein kinase kinase kinase 10Tumor necrosis factor ligand superfamily member 10
go.drugbank.com/bio_entities/BE0010497TargetHumansCytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG (PubMed:10549288, PubMed:26457518). Induces apoptosis. Its activity may be modulated by binding to the d...
Polypeptides: Tumor necrosis factor ligand superfamily member 10Istradefylline
go.drugbank.com/drugs/DB11757ApprovedInvestigationalIstradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. … [A184067] Istradefylline was granted FDA approval on 27 August 2019.[L8213]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates